$BTSG

KKR Phoenix Aggregator L.P. sold $857.5M of BTSG (indirect holdings)

KKR Phoenix Aggregator L.P. sold 14,669,771 indirectly-held shares of BrightSpring Health Services, Inc. (BTSG) at $58.45 ($857.49M total) on 2026-06-05.

Original reporting
SEC EDGAR · KKR Phoenix Aggregator L.P.
Published Jun 5, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BTSG
Bearish
medium confidence
Mentioned
$BTSG
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BTSGBearishMed
01

Why it matters

Traders may reassess short-term supply/demand and interpret the sale as a sentiment headwind, while fundamentals remain unchanged based on the filing alone.

02

Market read

A large, same-day disclosed sale by a 10% owner can drive near-term trading flows in BTSG even without new operating news.

03

What to watch

The filing lacks context on proceeds use, tax planning, or whether other holders are buying; price reaction may be muted if float impact is already absorbed.

Relevance 9/10Novelty 8/10Timing: Filed today (2026-06-05) for an open-market sale executed on 2026-06-05

Background

SEC Form 4 discloses a 10% owner’s open-market sale of BrightSpring Health Services shares; it notes no pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$BTSGBearishMedium confidence
Context

KKR Phoenix Aggregator L.P., a 10% owner of BrightSpring Health Services, sold 14,669,771 shares in an open-market transaction.

Expected impact

Mild-to-moderate downside bias for the next few sessions as traders price in supply, with limited follow-through absent additional catalysts.

Evidence & confidence

This is a Form 4 showing size and timing of a sale, but it does not cite earnings, guidance, or operational developments; also no 10b5-1 plan is indicated.

Market effects

Read-through is limited; this is company-specific ownership selling rather than a sector-wide signal.

No clear regional spillover indicated by the filing.

Primarily affects BTSG liquidity/sentiment; no global linkage stated.

Counterpoint

Large-holder sales can be routine liquidity events; without a 10b5-1 plan, the sale may still reflect diversification rather than negative fundamentals.

Key entities

  • BrightSpring Health Services, Inc.

    Subject of the Form 4 insider transaction; shares sold by a 10% owner.

  • KKR Phoenix Aggregator L.P.

    Reporting party executing the open-market sale of BTSG shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BTSGMedAI 8/10

BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?

BrightSpring Health Services (BTSG) stock has risen 59% YTD, outperforming industry and S&P 500. Q2 2026 revenues grew 23% to $3.9B, adjusted EBITDA up 44%. Growth driven by Specialty Pharmacy and Provider Services, with AI/automation improving efficiency. Leverage reduced to 2.15x. 2026 EPS estimates raised to $1.78 (78% growth). Risks include execution challenges and reimbursement pressures.

$BTSGMedAI 9/10

BrightSpring Health (BTSG) Q2 2026 Earnings Call Transcript

BrightSpring Health Services (BTSG) reported Q2 2026 net revenue of $3.873B, up 23%, and adjusted EBITDA of $205.5M, up 44.2%, with adjusted EPS of $0.45. FY2026 guidance raised to $15.1B-$15.425B revenue and $820M-$845M adjusted EBITDA. Net debt was $1.7B (2.15x leverage).

$BTSGMed

5 Revealing Analyst Questions From BrightSpring Health Services’s Q2 Earnings Call

BrightSpring Health Services (BTSG) reported Q2 revenue of $3.87B vs $3.66B expected and adjusted EPS of $0.45 vs $0.40, with adjusted EBITDA of $205.5M. The company raised full-year revenue guidance to $15.26B and EBITDA guidance to $832.5M. Management cited 30% Specialty and Infusion revenue growth and 31% script growth, while Home and Community Pharmacy faced customer exits and regulatory headwinds.

$BTSGMedAI 8/10

BTSG Raises 2026 Guidance as Specialty and Home Health Drive Growth

BrightSpring Health Services (BTSG) beat Q2 expectations with adjusted EPS of 45 cents (21.6% above consensus) and revenue of $3.87B (+23% YoY). It raised 2026 guidance to $15.10-$15.425B revenue and $820-$845M adjusted EBITDA. Specialty and infusion grew 30.1% and home health revenues rose 30.3%, while pharmacy fell 8% due to IRA impacts.